[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1, 2005

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(21):2596-2598. doi:10.1001/jama.293.21.2597-a

To the Editor: We have a number of concerns about the clinical features of the CREATE-ECLA trial.1 First, heparin used in coronary reperfusion therapy, such as the CREATE-ECLA patients received, blocks the key GIK physiological effect of lowering free fatty acids.2 Unfortunately, CREATE-ECLA did not report free fatty acid levels or look for this effect.

First Page Preview View Large
First page PDF preview
First page PDF preview